Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Patrick Sison / AP
A federal advisory panel on Monday recommended Medicare scrap a proposal that would slash drug payments to hospitals under the 340B drug pricing program by almost 30 percentage points next year. But it's worth noting that panel is made up of doctors and hospital executives who would be affected most.
Why it matters: The 340B program allows hospitals with a lot of poorer patients to buy drugs at cheaper prices and keep the savings, but it has come under fire in recent years by independent bodies and pharmaceutical groups who say hospitals are profiting excessively off the program. Medicare's proposal has ruffled a lot of feathers (hospitals say it does nothing to lower the high prices set by drug manufacturers), and it's becoming one of the bigger industry battles.
Looking ahead: Public comments on the proposal are due Sept. 11, and Medicare will issue its final rule in the fall.